1. |
|
|
2. |
- Mehta, A, et al.
(author)
-
Corrigendum
- 2019
-
In: Internal medicine journal. - : Wiley. - 1445-5994 .- 1444-0903. ; 49:8, s. 1059-1059
-
Journal article (other academic/artistic)
|
|
3. |
|
|
4. |
- Vellodi, A, et al.
(author)
-
Management of neuronopathic Gaucher disease : revised recommendations
- 2009
-
In: Journal of Inherited Metabolic Disease. - : Springer. - 0141-8955 .- 1573-2665. ; 32:5, s. 660-664
-
Journal article (peer-reviewed)abstract
- The original guidelines drawn up for the management of the neuronopathic forms of Gaucher disease were felt to be in need of revision; in particular, the role of high-dose enzyme replacement therapy (120 IU/kg of body weight every 2 weeks) in stabilizing neurological disease. The existing published evidence was analysed; it was concluded that it did not support the role of high-dose ERT, although this might be required to treat severe visceral disease.
|
|